cis-3-Methyl-cyclohexancarbonsaeure | 73873-48-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-3-Methyl-cyclohexancarbonsaeure
• 英文别名: (1S,3R)-3-Methylcyclohexane-1-carboxylic acid
• CAS: 73873-48-0
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: CIFSKZDQGRCLBN-RQJHMYQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pyrrolidine derivative or salt thereof
  申请人：Hachiya Shunichiro

  公开号：US20090062366A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).

  [问题] 提供一种可用于治疗钙敏感受体（CaSR）相关疾病，特别是甲状旁腺功能亢进症的化合物。 [解决方法] 发现了一种新型吡咯烷衍生物，其特征在于具有氨甲基基团，该基团被芳基烷基或类似物取代，或其盐，具有出色的CaSR激动调节活性，并且具有出色的选择性与CYP2D6抑制活性，可能导致药物相互作用。基于以上发现，这些新型吡咯烷衍生物可用作治疗CaSR相关疾病（甲状旁腺功能亢进症，肾性骨营养不良，高钙血症等）的治疗剂。
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20130065899A1

  公开（公告）日：2013-03-14

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物，其药学上可接受的组合物以及使用它们的方法。
• SYNTHESIS OF BIOBASED AND SUBSTITUTED TEREPHTHALIC ACIDS AND ISOPHTHALIC ACIDS
  申请人：BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY

  公开号：US20160031787A1

  公开（公告）日：2016-02-04

  Methods for producing bio-terephthalic acid and bio-isophthalic acid. Methods comprise a cycloaddition reaction to produce bio-4-methyl-3-cyclohexene-1-carboxylic acid, and bio-3-methyl-3-cyclohexene-1-carboxylic from bio-isoprene and bio-acrylic acid. An aromatization reaction produces bio-para-toluic acid and bio-meta-toluic acid from the bio-4-methyl-3-cyclohexene-1-carboxylic acid, and bio-3-methyl-3-cyclohexene-1-carboxylic. An oxidation reaction produces the bio-terephthalic acid and isophthalic acid from the bio-para-toluic acid and bio-meta-toluic acid.

  生产生物对苯二甲酸和生物异苯二甲酸的方法。该方法包括通过环加成反应从生物异戊二烯和生物丙烯酸中产生生物4-甲基-3-环己烯-1-羧酸和生物3-甲基-3-环己烯-1-羧酸。芳化反应从生物4-甲基-3-环己烯-1-羧酸和生物3-甲基-3-环己烯-1-羧酸中产生生物对甲基苯甲酸和生物间甲基苯甲酸。氧化反应从生物对甲基苯甲酸和生物间甲基苯甲酸中产生生物对苯二甲酸和生物异苯二甲酸。
• POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160264554A1

  公开（公告）日：2016-09-15

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了公式（I）的新型化合物，以及其药学上可接受的盐，溶剂合物，水合物，多晶形，共晶体，互变异构体，立体异构体，同位素标记衍生物，前药和其组合物。还提供了涉及本发明化合物或组合物的方法和试剂盒，用于治疗或预防主体中的增殖性疾病（例如，癌症（例如，白血病，淋巴瘤，黑色素瘤，多发性骨髓瘤，乳腺癌，尤因肉瘤，骨肉瘤，脑癌，神经母细胞瘤，肺癌），良性肿瘤，血管生成，炎症性疾病，自身炎症性疾病和自身免疫性疾病）。使用本发明化合物或组合物治疗患有增殖性疾病的主体可能抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如，细胞周期依赖性激酶7（CDK7），细胞周期依赖性激酶12（CDK12）或细胞周期依赖性激酶13（CDK13）），从而在主体中诱导细胞凋亡和/或抑制转录。
• 2,4-disubstituted pyrimidines useful as kinase inhibitors
  申请人：Celgene CAR LLC

  公开号：US10010548B2

  公开（公告）日：2018-07-03

  The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了可用作激酶抑制剂的 2,4-二取代嘧啶化合物、其药学上可接受的组合物以及使用方法。